BRPI1006266A2 - adsorvato, forma de dosagem, processo para a preparação de um adsorvato, processo para a preparação de uma forma de dosagem, uso de um adsorvato - Google Patents
adsorvato, forma de dosagem, processo para a preparação de um adsorvato, processo para a preparação de uma forma de dosagem, uso de um adsorvatoInfo
- Publication number
- BRPI1006266A2 BRPI1006266A2 BRPI1006266-1A BRPI1006266A BRPI1006266A2 BR PI1006266 A2 BRPI1006266 A2 BR PI1006266A2 BR PI1006266 A BRPI1006266 A BR PI1006266A BR PI1006266 A2 BRPI1006266 A2 BR PI1006266A2
- Authority
- BR
- Brazil
- Prior art keywords
- adsorbate
- dosage form
- preparing
- relates
- api
- Prior art date
Links
- 239000002156 adsorbate Substances 0.000 title abstract 9
- 239000002552 dosage form Substances 0.000 title abstract 8
- 238000004519 manufacturing process Methods 0.000 title abstract 5
- 238000000034 method Methods 0.000 title 1
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 abstract 3
- 208000030507 AIDS Diseases 0.000 abstract 2
- 241000725303 Human immunodeficiency virus Species 0.000 abstract 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 2
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 abstract 1
- 208000010228 Erectile Dysfunction Diseases 0.000 abstract 1
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 abstract 1
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 150000008280 chlorinated hydrocarbons Chemical class 0.000 abstract 1
- YMTINGFKWWXKFG-UHFFFAOYSA-N fenofibrate Chemical compound C1=CC(OC(C)(C)C(=O)OC(C)C)=CC=C1C(=O)C1=CC=C(Cl)C=C1 YMTINGFKWWXKFG-UHFFFAOYSA-N 0.000 abstract 1
- 229960002297 fenofibrate Drugs 0.000 abstract 1
- 201000001881 impotence Diseases 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 229960004844 lovastatin Drugs 0.000 abstract 1
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 abstract 1
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 abstract 1
- 239000012454 non-polar solvent Substances 0.000 abstract 1
- 229960002855 simvastatin Drugs 0.000 abstract 1
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 abstract 1
- IEHKWSGCTWLXFU-IIBYNOLFSA-N tadalafil Chemical compound C1=C2OCOC2=CC([C@@H]2C3=C([C]4C=CC=CC4=N3)C[C@H]3N2C(=O)CN(C3=O)C)=C1 IEHKWSGCTWLXFU-IIBYNOLFSA-N 0.000 abstract 1
- 229960000835 tadalafil Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Immunology (AREA)
- Virology (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Gynecology & Obstetrics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Molecular Biology (AREA)
- AIDS & HIV (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
adsorvato, forma de dosagem, processo para a preparação de um adsorvato, processo para a preparação de uma forma de dosagem, uso de um adsorvato a presente invenção pertence ao campo da indústria farmacêutica e refere-se às formas de dosagem compreendendo ingredientes farmaceuticamente ativos (api) como tadalafil, sinvastatina, fenofibrato e lovastatina que são praticamente insolúveis em água, adsorvidos em um veículo. além disso, ela refere-se a um adsorvato compreendendo api sendo praticamente insolúvel em água e a um processo para a preparação do dito adsorvato com solvente(s) não polar(es) tais como hidrocarboneto clorado, éter diisopropílico e hexano. além disso, a invenção refere-se a um processo para a preparação da forma de dosagem, bem como ao uso do adsorvato para a preparação da forma de dosagem. além disso, ela refere-se à forma de dosagem para uso no tratamento de disfunção erétil, infecções pelo vírus da imunodeficiência humana (hiv) e/ou síndrome da imunodeficiência adquirida (aids).
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09005047.7 | 2009-04-06 | ||
| EP09005047A EP2238979A1 (en) | 2009-04-06 | 2009-04-06 | Active pharmaceutical ingredient adsorbed on solid support |
| PCT/EP2010/054526 WO2010115886A1 (en) | 2009-04-06 | 2010-04-06 | Active pharmaceutical ingredient adsorbed on solid support |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI1006266A2 true BRPI1006266A2 (pt) | 2019-03-26 |
Family
ID=41210841
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI1006266-1A BRPI1006266A2 (pt) | 2009-04-06 | 2010-04-06 | adsorvato, forma de dosagem, processo para a preparação de um adsorvato, processo para a preparação de uma forma de dosagem, uso de um adsorvato |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20120088774A1 (pt) |
| EP (2) | EP2238979A1 (pt) |
| JP (1) | JP2012522825A (pt) |
| CN (1) | CN102448460A (pt) |
| AU (1) | AU2010233809B2 (pt) |
| BR (1) | BRPI1006266A2 (pt) |
| CA (1) | CA2757988C (pt) |
| EA (1) | EA031818B1 (pt) |
| MX (1) | MX2011010563A (pt) |
| WO (1) | WO2010115886A1 (pt) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE029842T2 (en) | 2007-02-23 | 2017-04-28 | Gilead Sciences Inc | Modulators of pharmacokinetic properties of therapeutics |
| PT2296633E (pt) | 2008-05-02 | 2015-12-04 | Gilead Sciences Inc | A utilização de partículas de portador sólido para melhorar a processabilidade de um agente farmacêutico |
| EP2672959A1 (en) | 2011-02-10 | 2013-12-18 | Synthon BV | Granulated composition comprising tadalafil and a disintegrant |
| RU2013141446A (ru) | 2011-02-10 | 2015-03-20 | Синтон Бв | Фармацевтическая композиция, содержащая тадалафил и циклодекстрин |
| WO2012107092A1 (en) | 2011-02-10 | 2012-08-16 | Synthon Bv | Pharmaceutical composition comprising tadalafil and a cyclodextrin |
| EP2672960A1 (en) * | 2011-02-10 | 2013-12-18 | Synthon BV | Pharmaceutical composition comprising tadalafil and a cyclodextrin |
| AU2012295397A1 (en) * | 2011-08-16 | 2014-02-20 | Merck Sharp & Dohme Corp. | Use of inorganic matrix and organic polymer combinations for preparing stable amorphous dispersions |
| EP3466951B1 (en) | 2014-07-23 | 2022-01-19 | KRKA, d.d., Novo mesto | A process for the preparation of cgmp-phosphodiesterase inhibitor and oral pharmaceutical formulation comprising tadalafil co-precipitates |
| EP3233059A1 (en) | 2014-12-19 | 2017-10-25 | Synthon B.V. | Pharmaceutical composition comprising amorphous lenalidomide |
| CN105380908B (zh) * | 2015-12-09 | 2018-08-10 | 河北大学 | 一种丁苯酞药物复合物及其制备方法和缓释制剂 |
| WO2018081190A1 (en) | 2016-10-25 | 2018-05-03 | The Procter & Gamble Company | Fibrous structures |
| WO2018081189A1 (en) | 2016-10-25 | 2018-05-03 | The Procter & Gamble Company | Fibrous structures |
| WO2020012243A2 (en) * | 2018-07-09 | 2020-01-16 | Abbott Laboratories Gmbh | Pharmaceutical composition containing a peptide |
| CN109528675B (zh) * | 2018-12-31 | 2020-12-22 | 杭州康本医药科技有限公司 | 一种他达拉非肠溶片剂及其制备方法 |
| CN113476408A (zh) * | 2021-07-23 | 2021-10-08 | 兆科药业（广州）有限公司 | 一种苯丁酸甘油酯颗粒剂及其制备方法与应用 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA72698B (en) * | 1972-02-03 | 1973-09-26 | Liebenberg R W | Method of preparing medicinal compositions |
| DE3485000D1 (de) | 1983-06-28 | 1991-10-10 | Takeda Chemical Industries Ltd | Gemahlene mischung. |
| JPS63119426A (ja) * | 1986-11-06 | 1988-05-24 | Mitsubishi Kasei Corp | 肝疾患治療薬組成物 |
| JP3886171B2 (ja) * | 1995-04-28 | 2007-02-28 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 薬剤組成物 |
| GB9511220D0 (en) | 1995-06-02 | 1995-07-26 | Glaxo Group Ltd | Solid dispersions |
| WO1996039126A2 (en) * | 1995-06-06 | 1996-12-12 | Warner-Lambert Company | Ranitidine salts on magnesium trisilicate as an adsorbate |
| US6821975B1 (en) | 1999-08-03 | 2004-11-23 | Lilly Icos Llc | Beta-carboline drug products |
| DE60238193D1 (de) * | 2001-06-22 | 2010-12-16 | Pfizer Prod Inc | Pharmazeutische zusammensetzungen, enthaltend adsorbate eines arzneimittels in amorpher form |
| WO2003055475A1 (en) * | 2002-01-03 | 2003-07-10 | Lek Pharmaceutical And Chemical Company D.D. | Controlled release pharmaceutical formulation containing venlafaxine |
| JP2007501218A (ja) * | 2003-08-04 | 2007-01-25 | ファイザー・プロダクツ・インク | 非晶質薬物の吸着物および親油性ミクロ相形成物質の医薬組成物 |
| EP1729766A1 (en) * | 2004-03-01 | 2006-12-13 | LEK Pharmaceuticals D.D. | Pharmaceutical formulation |
| WO2005116030A1 (en) * | 2004-05-31 | 2005-12-08 | Matrix Laboratories Ltd | A process for the preparation of tadalafil |
| KR20070072891A (ko) | 2004-11-02 | 2007-07-06 | 테바 파마슈티컬 인더스트리즈 리미티드 | 타달라필 결정형 및 이의 제조 방법 |
| EP1852118A1 (en) * | 2005-01-25 | 2007-11-07 | Kowa Company, Ltd. | Method for producing adsorptive porous body |
| WO2006091974A1 (en) | 2005-02-25 | 2006-08-31 | Teva Pharmaceutical Industries Ltd. | Tadalafil having a large particle size and a process for preparation thereof |
| US20070098804A1 (en) | 2005-08-29 | 2007-05-03 | Judith Aronhime | Solid particulate tadalafil having a bimodal particle size distribution |
| WO2008005039A1 (en) | 2006-07-07 | 2008-01-10 | Teva Pharmaceutical Industries Ltd. | Solid compositions comprising tadalafil and at least one carrier |
| US20110097414A1 (en) | 2007-02-26 | 2011-04-28 | Sandal Roshan Lal | Pharmaceutical compositions comprising adsorbate of fenofibrate |
| RU2456989C2 (ru) * | 2007-04-25 | 2012-07-27 | Тева Фармасьютикал Индастриес Лтд. | Твердые лекарственные формы, содержащие тадалафил |
| EP2072042A1 (en) * | 2007-12-21 | 2009-06-24 | Lek Pharmaceuticals D.D. | Active pharmaceutical ingredient on solid support, amorphous and with improved solubility |
-
2009
- 2009-04-06 EP EP09005047A patent/EP2238979A1/en not_active Ceased
-
2010
- 2010-04-06 EA EA201101432A patent/EA031818B1/ru not_active IP Right Cessation
- 2010-04-06 US US13/263,051 patent/US20120088774A1/en not_active Abandoned
- 2010-04-06 CA CA2757988A patent/CA2757988C/en not_active Expired - Fee Related
- 2010-04-06 WO PCT/EP2010/054526 patent/WO2010115886A1/en not_active Ceased
- 2010-04-06 EP EP10713900A patent/EP2416775A1/en not_active Withdrawn
- 2010-04-06 MX MX2011010563A patent/MX2011010563A/es active IP Right Grant
- 2010-04-06 JP JP2012503994A patent/JP2012522825A/ja active Pending
- 2010-04-06 BR BRPI1006266-1A patent/BRPI1006266A2/pt not_active IP Right Cessation
- 2010-04-06 CN CN2010800227528A patent/CN102448460A/zh active Pending
- 2010-04-06 AU AU2010233809A patent/AU2010233809B2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| JP2012522825A (ja) | 2012-09-27 |
| AU2010233809B2 (en) | 2015-03-12 |
| WO2010115886A1 (en) | 2010-10-14 |
| EP2238979A1 (en) | 2010-10-13 |
| EP2416775A1 (en) | 2012-02-15 |
| CN102448460A (zh) | 2012-05-09 |
| MX2011010563A (es) | 2012-01-20 |
| US20120088774A1 (en) | 2012-04-12 |
| EA201101432A1 (ru) | 2012-04-30 |
| CA2757988A1 (en) | 2010-10-14 |
| CA2757988C (en) | 2018-06-19 |
| AU2010233809A1 (en) | 2011-11-10 |
| EA031818B1 (ru) | 2019-02-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI1006266A2 (pt) | adsorvato, forma de dosagem, processo para a preparação de um adsorvato, processo para a preparação de uma forma de dosagem, uso de um adsorvato | |
| MX2018005708A (es) | Compuesto de 7-(tiazol-5-il)pirrolopirimidina como agonista de tlr7. | |
| GT201200158A (es) | Procedimiento para la preparación de {4,6-diamino-2-[1-(2-fluorobencil)-1h-pirazolo[3,4-b]piridin-3-il]pirimidin-5-il}metilcarbamato de metilo y su purificación para su uso como principio activo farmacéutico | |
| EA201290131A1 (ru) | Производные пурина или деазапурина для применения при лечении вирусных инфекций и других заболеваний | |
| CL2017002709A1 (es) | Compuestos de pirazolo - y triazolo - pirimidina antivirales contra vsr | |
| CL2013001339A1 (es) | Compuestos derivados heterociclicos condensados, con actividad antiviral; composicion farmaceutica que los comprende; y su uso para la prevencion o tratamiento de la infeccion de vih. | |
| CL2013001338A1 (es) | Compuestos derivados de benzotieno-piridinas sustituidas, inhibidores de la replicacion del vih; composicion farmaceutica que los comprende; combinacion farmaceutica; kit farmaceutico; y su uso para el tratamiento del vih. | |
| SV2010003581A (es) | 4-(4-ciano-2-tioaril)dihidropirimidinonas y su uso | |
| CL2015001756A1 (es) | Compuestos derivados de carbamoilpiridona policiclicos; composicion farmaceutica que los comprende; y su uso para el tratamiento de una infeccion de vih en un humano que tiene o se encuentra en riesgo de tener la infeccion. | |
| CL2011000301A1 (es) | Compuestos derivados de purina con actividad inmunomoduladora; composición farmacéutica que los comprende; y uso de ellos en el tratamiento de enfermedades alérgicas, rinitis alérgica, asma, enfermedades infecciosas y cáncer. | |
| BR112015000615A2 (pt) | purinas macrocíclicas para o tratamento de infecções virais | |
| BR112016028961A8 (pt) | fibras eletrotorcidas, seu método de preparação e seu uso, bem como composição, e kit | |
| GT201200313A (es) | 5-fluoro-1h-pirazolopiridinas sustituidas y su uso | |
| BR112015020118A2 (pt) | derivados de 2-aminopirimidina para o tratamento de infecções virais | |
| CR11731A (es) | Composiciones y procedimientos para su preparación y uso | |
| BR112013025987A2 (pt) | derivados de pirimidina para o tratamento de infecções virais | |
| CL2013001935A1 (es) | Formulacion ácida acuosa que comprende un primer péptido enlazado a fluorocarburo; metodo para obtener dicha formulación; uso de dicha formulación para tratar o prevenir infeccion patógena, una enfermedad autoinmunitaria o cancer. | |
| EP4309736A3 (en) | Crystalline forms of (2r,5s,13ar)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido [1',2':4,5]pyrazino [2,1-b][1,3]oxazepine-10-carboxamide | |
| NZ601319A (en) | Antiviral combinations involving (4r,12as)-n-[(2,4-difluorophenyl)methyl]-3,4,6,8,12,12a-hexahydro-7-hydroxy-4-methyl-6,8-dioxo-2h-pyrido[1’,2’:4,5]pyrazino[2,1-b][1,3]oxazine-9-carboxamide | |
| CL2008001123A1 (es) | Compuestos derivados de acido lipoico; formulacion farmaceutica que lo comprende; y uso en el tratamiento del cancer. | |
| ES2524385R1 (es) | Composición farmacéutica y su uso para preparar un medicamento destinado al tratamiento y la prevención de enfermedades causadas por el VIH | |
| PE20150167A1 (es) | (r)-nifuratel, su uso para el tratamiento de las infecciones y sintesis de (r) y (s)-nifuratel | |
| CL2013002129A1 (es) | Compuestos derivados de acido 3-heteroaroilamino-propionico sustituidos, como inhibidores de la proteasa catepsina a; procedimiento de preparacion; composicion farmaceutica que los comprende; y su uso para el tratamiento de insuficiencia cardiaca, enfermedades inmunologicas, asma, dolor, entre otras. | |
| ES2555557R1 (es) | Fármaco y uso para preparar un medicamento destinado a la prevención de la infección del VIH y al tratamiento de enfermedades causadas por el VIH, incluido el SIDA | |
| CL2012002954A1 (es) | Compuestos derivados de heterobiaril-ciclohexil-tetraazabenzo[e]azules sustituidos, modulares del receptor de vasopresina v1a; procedimiento de preparacion; composicion farmaceutica; y su uso para la prevencion o el tratamient5o de la dismenorrea, disfuncion sexual masculina o femenina, ansiedad, hipertension, entre otros. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 10A ANUIDADE. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2561 DE 2020-02-04 |
|
| B350 | Update of information on the portal [chapter 15.35 patent gazette] |